← Back to Search

Monoclonal Antibodies

Radiolabeled Monoclonal Antibody Therapy for Non-Small Cell Lung Cancer

Phase 1

Waitlist Available

Research Sponsored by Garden State Cancer Center at the Center for Molecular Medicine and Immunology

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients with stage IIIA/B unresectable disease who received prior radiotherapy must show evidence of progressive disease (greater than 25% increase in primary tumor or appearance of new lesions)

No known, active brain metastases

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is studying how well radiolabeled monoclonal antibody therapy works in treating patients with non-small cell lung cancer that has returned or is not responding to treatment.

Who is the study for?

This trial is for adults over 18 with advanced non-small cell lung cancer that's worsened after standard chemotherapy. They should have a life expectancy of at least 3 months, no active brain metastases or serious liver issues, and must not be pregnant or nursing. Participants need normal organ function and blood counts, are HIV negative, and agree to use contraception.Check my eligibility

What is being tested?

The study tests radiolabeled monoclonal antibody therapy in patients with relapsed or refractory non-small cell lung cancer. It aims to see if this treatment can target and kill cancer cells without harming healthy ones.See study design

What are the potential side effects?

Potential side effects may include reactions related to the immune system targeting normal cells by mistake, radiation exposure from the labeled antibodies affecting healthy tissues, fatigue, allergic responses to the monoclonal antibody component, as well as typical infusion-related reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My stage IIIA/B cancer has grown more than 25% or spread after radiotherapy.

Select...

I do not have any active cancer spread to my brain.

Select...

My lung function tests show at least 60% FEV1 and 50% DLCO.

Select...

My kidney function, measured by creatinine, is within normal limits.

Select...

My liver functions are within normal limits and I don't have hepatitis B or C.

Select...

I am 18 years old or older.

Select...

I've had one round of standard chemotherapy and, if needed, limited chest radiation.

Select...

My cancer is not adenocarcinoma, but tests show high CEA levels or positive CEA in tissue.

Select...

I do not suffer from severe loss of appetite, nausea, or vomiting.

Select...

My heart pumps well, with an ejection fraction of 50% or more.

Select...

My lung cancer is confirmed to be non-small cell type.

Select...

I can take care of myself and perform daily activities.

Select...

Less than a quarter of my bone marrow is affected by cancer.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 13Eligibility criteria met

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH

13,665 Previous Clinical Trials

40,925,854 Total Patients Enrolled

Garden State Cancer Center at the Center for Molecular Medicine and ImmunologyLead Sponsor

9 Previous Clinical Trials

123 Total Patients Enrolled

Jack D. Burton, MDStudy ChairGarden State Cancer Center at the Center for Molecular Medicine and Immunology

8 Previous Clinical Trials

114 Total Patients Enrolled

Media Library

Radiolabeled Monoclonal Antibody Therapy (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT00006458 — Phase 1

Lung Cancer Clinical Trial 2023: Radiolabeled Monoclonal Antibody Therapy Highlights & Side Effects. Trial Name: NCT00006458 — Phase 1

Radiolabeled Monoclonal Antibody Therapy (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00006458 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has this therapy been validated by the FDA?

"The safety of this novel treatment is estimated to be a 1 on the scale, as it has only been evaluated in Phase One clinical trials and there remains limited data supporting its efficacy."

Answered by AI

Is this trial actively seeking participants?

"This clinical trial, originally posted on August 1st 2000 and last updated February 28th 2009, is not actively recruiting. Nonetheless, there are 2042 other medical studies that are available for participation at this moment in time."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer

2000. "Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00006458.

All > Lung > Sclc